SHAREHOLDER NOTICE: Faruqi & Faruqi, LLP Investigates Claims on Behalf of Investors of Cerevel Therapeutics

Core Viewpoint - A class action lawsuit has been filed against Cerevel Therapeutics Holdings, Inc., Bain Capital Investors, LLC, and Pfizer, Inc. for alleged violations of federal securities laws, particularly concerning misleading statements and undisclosed material facts related to Cerevel's stock offerings and acquisition processes [1][5][6]. Group 1: Legal Actions and Allegations - The class action targets investors who sold or held Cerevel stock during specific periods, claiming damages due to violations of the Securities Exchange Act of 1934 [1][3]. - The complaint alleges that Bain acquired Cerevel shares during a secondary stock offering while possessing nonpublic information about AbbVie's acquisition interest, leading to significant profits for Bain when the acquisition was later disclosed at $45 per share [5][6]. - The January 18, 2024, Proxy statement for the AbbVie acquisition is claimed to have misled investors regarding the sales process and conflicts of interest, suggesting that Bain and Pfizer orchestrated the process to maximize profits at the expense of public shareholders [5][6]. Group 2: Firm Information and Contact - Faruqi & Faruqi, LLP is a national securities law firm with a history of recovering hundreds of millions for investors since its establishment in 1995 [4]. - The firm encourages individuals with information regarding Cerevel's conduct to come forward, including whistleblowers and former employees [8].